The definitive 2026 guide to senolytic supplements. Covering the Mayo Clinic Fisetin protocol, TAME trial updates, and the top-rated fisetin, quercetin, and combination products backed by clinical research.
Every cell in your body has an expiration date — but some refuse to die. Senescent cells, often called "zombie cells," are cells that have stopped dividing yet linger in your tissues, secreting a toxic cocktail of inflammatory signals known as the senescence-associated secretory phenotype (SASP). Over time, this chronic low-grade inflammation accelerates tissue damage, disrupts organ function, and drives many of the hallmarks of aging: joint stiffness, reduced immune function, cognitive decline, and increased cancer risk.
Enter senolytics — a class of compounds that selectively trigger apoptosis (programmed cell death) in senescent cells while leaving healthy cells intact. Over the past decade, landmark research from Mayo Clinic, the Salk Institute, and the University of Minnesota has transformed senolytics from a niche biohacking interest into one of the most actively studied areas in longevity medicine. This guide covers the latest 2026 clinical protocol updates, what the evidence says about each leading senolytic compound, and which specific products to consider for your protocol. For a broader look at how senescent cells relate to aging, read our guide to zombie cells and aging.
The most widely referenced senolytic protocol in the research literature is the intermittent high-dose approach pioneered by Dr. James Kirkland and colleagues at Mayo Clinic. Unlike daily antioxidant supplements, senolytics work via a "hit-and-run" mechanism: you take a high dose for a short window (2–3 consecutive days), achieve peak tissue concentrations sufficient to trigger apoptosis in senescent cells, then stop. Healthy cells recover; zombie cells do not.
Standard Mayo Clinic-Inspired Fisetin Protocol:
Beginner Ramp-Up Schedule:
1. Month 1: 500 mg/day × 2 days (tolerance test)
2. Month 2: 1,000 mg/day × 2 days
3. Month 3+: 1,500–2,000 mg/day × 2 days (maintenance dose)
The rationale for pulsed dosing is critical: fisetin must reach a threshold tissue concentration to activate senolytic pathways. Chronic low doses (100–200 mg/day) do not achieve these concentrations and likely confer only mild antioxidant benefits — not true senolytic effects. For a step-by-step beginner's protocol, see our complete senolytic protocol guide.
The Targeting Aging with Metformin (TAME) trial, led by Dr. Nir Barzilai at the Albert Einstein College of Medicine, represents a watershed moment in longevity science. TAME is the first clinical trial designed to use the FDA's emerging "aging as an indication" framework — meaning the trial treats aging itself as the condition being targeted, not individual diseases. With over 3,000 participants tracked for 6 years, TAME aims to demonstrate that metformin can delay the development of multiple age-related conditions simultaneously (cardiovascular disease, cancer, dementia, and functional decline).
2026 TAME Update:
Read our dedicated Metformin and the TAME Trial explainer for the full picture.
A 2024 study published in *Nature Aging* confirmed fisetin as the most potent natural senolytic compound tested to date, outperforming quercetin, luteolin, and resveratrol in reducing senescent cell markers in both cell culture and mouse models. Key findings:
The cognitive and metabolic benefits of fisetin are being actively studied: early human data suggests improvements in memory recall and insulin sensitivity after multi-cycle protocols, though larger randomized trials are needed.
Quercetin's senolytic efficacy depends critically on bioavailability. Standard quercetin has poor oral absorption (~10–20%). The phytosome form (quercetin complexed with phosphatidylcholine from sunflower lecithin) achieves 20× higher plasma concentrations versus standard quercetin, making it the only form considered clinically relevant for senolytic applications without concurrent dasatinib.
The following products represent the current best options across three categories, based on formulation science, purity standards, and alignment with established senolytic protocols.
| | Product 1 | Product 2 | Product 3 |
| Primary Compound | Fisetin (Novusetin Extract) | Quercetin Phytosome | Fisetin + Quercetin + Apigenin |
| Dose per Serving | 500–1,000 mg | 250–500 mg (phytosome) | Combination blend |
| Bioavailability | High (standardized extract) | Very High (20× standard) | Synergistic blend |
| Best For | Solo fisetin protocol | D+Q alternative | Comprehensive coverage |
| Protocol Fit | Mayo Clinic protocol | Monthly cycling | Quarterly maintenance |
| Price Range | $–$$ | $$ | $–$$ |
Novusetin is a patented, pharmaceutical-grade fisetin extract standardized to ≥98% purity — the form used in Mayo Clinic-affiliated research. Unlike commodity fisetin supplements, Novusetin specifies the botanical source (*Cotinus coggygria*, smoke tree bark), provides Certificates of Analysis, and is manufactured in GMP-certified facilities. For a protocol targeting genuine senolytic clearance, the purity and standardization of Novusetin-based products is the gold standard.
Key specs:
Dosing: 1,000–2,000 mg/day for 2 consecutive days monthly.
The gold-standard senolytic combination in clinical research is dasatinib + quercetin (D+Q). Since dasatinib is a prescription oncology drug, the practical over-the-counter alternative is high-absorption quercetin phytosome, which achieves plasma concentrations in the range shown to have senolytic activity. This form is the backbone of many community-adopted Q-only protocols and is the preferred quercetin form among longevity physicians who want to combine it with fisetin for enhanced synergy.
Key specs:
Dosing: 500–1,000 mg phytosome/day for 2–3 consecutive days monthly.
For those who prefer comprehensive coverage in a single product, combined senolytic complexes stack multiple compounds that target overlapping but distinct anti-apoptotic survival pathways. The most studied combination includes fisetin (targets BCL-2/BCL-xL pathways), quercetin (targets PI3K/Akt and BCL-2 pathways), and apigenin (targets NF-κB and ERK signaling) — providing three complementary mechanisms of senescent cell clearance.
Key specs:
Dosing: Follow manufacturer's protocol; typically 2–3 consecutive days per quarter.
Start here: If you are new to senolytics and want the closest alignment with published research, Product 1 (Novusetin Fisetin) is the clear starting point. The Mayo Clinic protocol data is built on high-purity fisetin, and Novusetin provides that standardization.
For enhanced clearance: Once you have completed 3–6 cycles with fisetin alone, consider adding Product 2 (Quercetin Phytosome) on senolytic days. This fisetin + quercetin combination targets more anti-apoptotic pathways and mirrors the published D+Q research as closely as possible with OTC supplements.
For maintenance cycling: After an initial 6-month clearing phase, many practitioners switch to quarterly dosing using a combined complex (Product 3) for convenience, reserving the higher-dose mono-ingredient protocols for annual "deep clearing" cycles.
There are no consumer-grade senescent cell burden tests yet. Practical indicators include: reductions in hs-CRP and IL-6 (inflammatory markers) on a standard blood panel, improvements on epigenetic age tests (TruAge, Levine PhenoAge), and subjective markers like reduced joint stiffness, improved energy, and faster exercise recovery. Track these metrics before starting and every 3–6 months.
Always with food. Both fisetin and quercetin are fat-soluble flavonoids. Taking them with a meal containing healthy fats (olive oil, avocado, eggs, fatty fish) can increase absorption 5–10×. Taking on an empty stomach wastes most of the dose.
Yes — this is the "maximal clearance" approach used by advanced biohackers. A typical stacked senolytic day might include 1,000 mg fisetin + 500 mg quercetin phytosome taken together with a high-fat breakfast, repeated for 2 consecutive days monthly. Do not exceed this without medical supervision and do not add a combined complex on top (you would be tripling up on the same compounds).
The pulsed protocol approach (2 days/month or 2–3 days/quarter) is generally considered safe for healthy adults over 40 based on available human data. There are no published long-term safety trials in healthy populations. People on prescription medications should consult a physician, as both fisetin and quercetin inhibit CYP3A4 and can alter drug metabolism. For the full risk-benefit picture, see our Fisetin intervention page (Moderate evidence) and our Quercetin intervention page (Good evidence).
Most longevity physicians recommend senolytics for adults over 40, when senescent cell accumulation begins to accelerate measurably. Younger adults generally benefit more from prevention strategies — exercise, sleep, nutrition, stress management — rather than clearance protocols. See our complete longevity intervention rankings for the full evidence-based priority order.
In 2026, the senolytic supplement landscape is more sophisticated and better evidenced than it has ever been. The Mayo Clinic fisetin protocol provides a rigorous, research-backed framework for pulsed dosing. The TAME trial is normalizing the idea of targeting aging itself as a modifiable condition. And the availability of high-purity Novusetin extract, pharmaceutical-grade quercetin phytosome, and comprehensive senolytic complexes means consumers have genuinely effective options for the first time.
Start with Novusetin Fisetin if you want the most research-aligned protocol. Add Quercetin Phytosome once you are ready to expand to a dual-compound approach. Use a Senolytic Complex for convenient quarterly maintenance. Above all: prioritize quality over cost, follow a pulsed protocol, and take your supplements with fat. The zombie cells you clear today are the inflammation you avoid tomorrow.
*Disclaimer: As an Amazon Associate, we earn from qualifying purchases. This article is for informational purposes only and does not constitute medical advice.*